Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)

Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present) Full article

Journal

Expert Opinion on Therapeutic Patents
ISSN: 1744-7674

Output data

Year: 2025, Volume: 35, Number: 2, Pages: 111-136 Pages count : 26 DOI: 10.1080/13543776.2024.2446228

Authors

Ivanenkov Yan A. ^1,2 , Malyshev Alexander S. ^1,2 , Terentiev Victor A. ^1,2 , Korzhenevskaya Anastasia A. ³ , Evteev Sergei A. ^1,2 , Vatsadze Sergey Z. ⁴ , Medved’ko Aleksei V. ⁴ , Shegai Petr V. ¹ , Kaprin Andrey D. ^1,3

Affiliations

1	P. Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation
2	The Federal State Unitary Enterprise Dukhov Automatics Research Institute, Moscow, Russian Federation
3	Peoples' Friendship University of Russia (RUDN), Moscow, Russian Federation
4	N.D. Zelinsky Institute of Organic Chemistry, Moscow, Russian Federation

The ataxia telangiectasia mutated kinase (ATM) is key in coordinating the DDR signaling network essential for responding to double-strand breaks (DSBs). Several ATM inhibitors are being investigated for potential anticancer treatment in clinical trials.

Ivanenkov Y.A. , Malyshev A.S. , Terentiev V.A. , Korzhenevskaya A.A. , Evteev S.A. , Vatsadze S.Z. , Medved’ko A.V. , Shegai P.V. , Kaprin A.D.
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)
Expert Opinion on Therapeutic Patents. 2025. V.35. N2. P.111-136. DOI: 10.1080/13543776.2024.2446228 WOS OpenAlex

Web of science:	WOS:001391334800001
OpenAlex:	W4405828748

Пока нет цитирований